- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
Correlation analysis between PSGL-1 and cutaneous malignant melanoma
- Acta Scientiarum Naturalium Universitatis Sunyatseni Vol. 63, Issue 5, Pages: 83-89(2024)
- 作者机构：
首都医科大学附属北京中医医院肿瘤科，北京 100010
- 作者简介：
- 基金信息：
DOI：10.13471/j.cnki.acta.snus.ZR20240041
CLC： R73Published：25 September 2024，
Published Online：22 April 2024，
Received：04 February 2024，
Accepted：24 March 2024
- 稿件说明：
移动端阅览
刘梓燊,郑瑛瑛,袁梦琪等.PSGL-1与皮肤恶性黑色素瘤预后的相关性分析[J].中山大学学报(自然科学版)(中英文),2024,63(05):83-89.
LIU Zishen,ZHENG Yingying,YUAN Mengqi,et al.Correlation analysis between PSGL-1 and cutaneous malignant melanoma[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2024,63(05):83-89.
刘梓燊,郑瑛瑛,袁梦琪等.PSGL-1与皮肤恶性黑色素瘤预后的相关性分析[J].中山大学学报(自然科学版)(中英文),2024,63(05):83-89. DOI： 10.13471/j.cnki.acta.snus.ZR20240041.
LIU Zishen,ZHENG Yingying,YUAN Mengqi,et al.Correlation analysis between PSGL-1 and cutaneous malignant melanoma[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2024,63(05):83-89. DOI： 10.13471/j.cnki.acta.snus.ZR20240041.
摘要
为了探究PSGL-1与皮肤恶性黑色素瘤预后是否具有相关性，从全基因组关联研究（GWAS）提取PSGL-1和皮肤恶性黑色素瘤的遗传数据，使用逆方差加权法、MR-Egger回归法、加权中位数法、加权模式法和简单模式法进行分析，并对数据进行敏感性分析。从TCGA数据库提取皮肤恶性黑色素瘤的生存信息，根据PSGL-1表达高低进行分组，通过Kaplan-Meier法绘制生存曲线，Log-rank检验比较两者生存期之间的差异。通过体外实验探究PSGL-1对A375细胞生物学功能影响。结果显示PSGL-1对皮肤恶性黑色素瘤的逆方差加权法分析结果为OR=0.666，95% CI（0.494～0.899），
P
=0.008。PSGL-1高表达组中位生存期为44.70个月，PSGL-1低表达组中位生存期为29.13个月，
P
=0.000 2。PSGL-1体外抑制A375细胞的迁移。研究结果发现PSGL-1表达增高是皮肤恶性黑色素瘤的保护因素，是一种潜在的皮肤黑色素瘤预后标志物。
Abstract
To investigate whether PSGL-1 is correlated with the prognosis of cutaneous malignant melanoma. Genetic data of PSGL-1 and cutaneous malignant melanoma were extracted from genome-wide association studies （GWAS） and analyzed using inverse variance weighting， MR-Egger regression， weighted median， weighted mode， and simple mode metho
ds， and sensitivity analyses were performed on the data. Survival information of cutaneous malignant melanoma was extracted from the TCGA database， and grouped according to high and low PSGL-1 expression， survival curves were plotted by the Kaplan-Meier method， and the Log-rank test was used to compare the difference between the two survival periods. Exploring the effects of PSGL-1 on the biological functions of A375 cells through
in vitro
experiments. The inverse variance weighted method analysis of PSGL-1 on cutaneous malignant melanoma resulted in OR=0.666， 95% CI （0.494-0.899），
P
=0.008. The median survival was 44.70 months in the PSGL-1 high expression group and 29.13 months in the PSGL-1 low expression group，
P
= 0.000 2. PSGL-1 inhibits the migration of A375 cells in vitro. Increased PSGL-1 expression is a protective factor against cutaneous malignant melanoma and is a potential prognostic marker for cutaneous melanoma.
关键词
PSGL-1皮肤恶性黑色素瘤孟德尔随机化TCGA数据库
Keywords
PSGL-1cutaneous malignant melanomaMendelian randomization studyTCGA database
references
沙姗姗， 李军， 陶娟， 2021. 黑素瘤免疫治疗的难点及对策［J］. 中华皮肤科杂志， 54（4）： 313-317.
闫秀文， 赵艺璞， 李亚军， 等， 2022. 血清PSGL-1、ANXA1、PCT对COPD急性发作并发肺部感染的诊断价值［J］. 分子诊断与治疗杂志， 14（2）： 274-277+ 281.
BURGESS S， SMITH G D， DAVIES N M， et al， 2023. Guidelines for performing Mendelian randomization investigations： Update for summer 2023［J］. Wellcome Open Res， 4： 186.
CARLISLE R， SEYMOUR L W， COUSSIOS C C， 2013. Targeting of liposomes via PSGL1 for enhanced tumor accumulation［J］. Pharm Res， 30（2）： 352-361.
CHI Z， LI S， SHENG X， et al， 2011. Clinical presentation， histology， and prognoses of malignant melanoma in ethnic Chinese： A study of 522 consecutive cases［J］. BMC Cancer， 11： 85.
DeROGATIS J M， VIRAMONTES K M， NEUBERT E N， et al， 2022. Targeting the PSGL-1 immune checkpoint promotes immunity to PD-1-resistant melanoma［J］. Cancer Immunol Res， 10（5）： 612-625.
FENG R， LU M， XU J， et al， 2022. Pulmonary embolism and 529 human blood metabolites： Genetic correlation and two-sample Mendelian randomization study［J］. BMC Genom Data， 23（1）： 69.
GILLY A， PARK Y C， PNG G， et al， 2020. Whole-genome sequencing analysis of the cardiometabolic proteome［J］. Nat Commun， 11（1）： 6336.
GOETZ D J， GREIF D M， DING H， et al， 1997. Isolated P-selectin glycoprotein ligand-1 dynamic adhesion to P- and E-selectin［J］. J Cell Biol， 137（2）： 509-519.
HOPE J L， OTERO D C， BAE E A， et al， 2023. PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion［J］. Cell Rep， 42（5）： 112436.
JOHNSTON R J， SU L J， PINCKNEY J， et al， 2019. VISTA is an acidic pH-selective ligand for PSGL-1［J］. Nature， 574（7779）： 565-570.
LARKIN J， CHIARION-SILENI V， GONZALEZ R， et al， 2019. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma［J］. N Engl J Med， 381（16）： 1535-1546.
LAW M H， MACGREGOR S， HAYWARD N K， 2012. Melanoma genetics： Recent findings take us beyond well-traveled pathways［J］. J Invest Dermatol， 132（7）： 1763-1774.
LI X， CHEN X， GONG S， et al， 2023. Platelets promote CRC by activating the C5a/C5aR1 axis via PSGL-1/JNK/STAT1 signaling in tumor-associated macrophages［J］. Theranostics， 13（6）： 2040-2056.
MANTOVANI A， ALLAVENA P， MARCHESI F， et al， 2022. Macrophages as tools and targets in cancer therapy［J］. Nat Rev Drug Discov， 21（11）： 799-820.
NUÑEZ-ANDRADE N， LAMANA A， SANCHO D， et al， 2011. P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria［J］. J Pathol， 224（2）： 212-221.
SAKAUE S， KANAI M， TANIGAWA Y， et al， 2021. A cross-population atlas of genetic associations for 220 human phenotypes［J］. Nat Genet， 53（10）： 1415-1424.
SI L， ZHANG X， SHU Y， et al， 2019. A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma （KEYNOTE-151）［J］. Transl Oncol， 12（6）： 828-835.
SPERTINI O， CORDEY A S， MONAI N， et al， 1996. P-selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils， monocytes， and CD34+ hematopoietic progenitor cells［J］. J Cell Biol， 135（2）： 523-531.
STIVALA S， GOBBATO S， BONETTI N， et al， 2022. Dietary alpha-linolenic acid reduces platelet activation and collagen-mediated cell adhesion in sickle cell disease mice［J］. J Thromb Haemost， 20（2）： 375-386.
SUNG H， FERLAY J， SIEGEL R L， et al， 2021. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 71（3）： 209-249.
TANG B， YAN X， SHENG X， et al， 2019. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients［J］. J Hematol Oncol， 12（1）： 7.
TÍMÁR J， LADÁNYI A， 2022. Molecular pathology of skin melanoma： Epidemiology， differential diagnostics， prognosis and therapy prediction［J］. Int J Mol Sci， 23（10）： 5384.
TINOCO R， CARRETTE F， BARRAZA M L， et al， 2016. PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion［J］. Immunity， 44（5）： 1190-1203.
TINOCO R， OTERO D C， TAKAHASHI A A， et al， 2017. PSGL-1： A new player in the immune checkpoint landscape［J］. Trends Immunol， 38（5）： 323-335.
TOPALIAN S L， HODI F S， BRAHMER J R， et al， 2012. Safety， activity， and immune correlates of anti-PD-1 antibody in cancer［J］. N Engl J Med， 366（26）： 2443-2454.
WANG L， RUBINSTEIN R， LINES J L， et al， 2011. VISTA， a novel mouse Ig superfamily ligand that negatively regulates T cell responses［J］. J Exp Med， 208（3）： 577-592.
WOLCHOK J D， CHIARION-SILENI V， GONZALEZ R， et al， 2022. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma［J］. J Clin Oncol， 40（2）： 127-137.
XIA L， RAMACHANDRAN V， McDANIEL J M， et al， 2003. N-terminal residues in murine P-selectin glycoprotein ligand-1 required for binding to murine P-selectin［J］. Blood， 101（2）： 552-559.
YE Z， GUO H， WANG L， et al， 2022. GALNT4 primes monocytes adhesion and transmigration by regulating O-Glycosylation of PSGL-1 in atherosclerosis［J］. J Mol Cell Cardiol， 165： 54-63.
ZHANG X， ZHU M， JIANG X L， et al， 2020. P-selectin glycoprotein ligand 1 deficiency prevents development of acute pancreatitis by attenuating leukocyte infiltration［J］. World J Gastroenterol， 26（41）： 6361-6377.
0
Views
106
下载量
0
CSCD
- L-PDFDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Postal code：510275
- Tel：020-84112585，84113223 Email：xuebaozr@mail.sysu.edu.cn
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
